Hdl for the treatment of stroke and other ischemic conditions

Abstract

The present invention relates to a method for the prophylaxis and/or treatment of stroke and other ischemic injury, wherein HDL is administered to a subject in need thereof, particularly by intravenous infusion.

1 . Use of HDL for the manufacture of an agent for the prophylaxis and/or treatment of ischemia or reperfusion injury.  
     
     
         2 . The use of  claim 1  for the prophylaxis and/or treatment of a disorder selected from ischemic stroke, ischemic tissue injury, cardiac ischemia, cardiac reperfusion injury, and complications resulting from organ transplantation or cardio-pulmonary bypass surgery.  
     
     
         3 . The use of  claim 1  wherein HDL is administered by intravenous infusion and/or injection.  
     
     
         4 . The use of  claim 1  wherein HDL is administered as a prophylaxis.  
     
     
         5 . The use of  claim 1  wherein HDL is administered as a treatment.  
     
     
         6 . The use of  claim 1  wherein HDL is administered before the start of ischemia and/or during ischemia.  
     
     
         7 . The use of  claim 1  wherein HDL is administered at or after reperfusion.  
     
     
         8 . The use of any of  claim 1  wherein HDL is administered in a dosage of from 10-200 mg HDL (weight based on apolipoprotein) per kg body weight per treatment.  
     
     
         9 . The use of  claim 1  wherein HDL is administered as a bolus injection and/or as an infusion for a clinically necessary period of time.  
     
     
         10 . The use of  claim 1  wherein the HDL has a molar ratio of protein, e.g. apolipoprotein A-1 to phospholipids in the range of 1:50-1:250 and optionally additional lipids such as cholesterol, cholesterol esters, trigylcerides and/or sphingolipids are present in a molar ratio of up to 1:20 based on the protein.  
     
     
         11 . The use of  claim 1 , wherein the HDL is selected from nascent HDL, reconstituted HDL (rHDL), recombinant HDL or mixtures thereof.  
     
     
         12 . The use of  claim 1 , wherein HDL is administered in combination with other pharmaceutical agents.  
     
     
         13 . A method for prophylaxis and/or treatment of ischemia or reperfusion injury comprising administering a subject in need thereof an effective amount of HDL.  
     
     
         14 . The method of  claim 13 , wherein the HDL is selected from nascent HDL, reconstituted HDL (rHDL), recombinant HDL or mixtures thereof.  
     
     
         15 . The method of  claim 13 , wherein the subject is a human.  
     
     
         16 . A composition for the prophylaxis and/or treatment of ischemia or reperfusion injury comprising HDL as an active ingredient.